How the FDA's Compounding Proposal Affects Your GLP-1 Prescription

If you're getting compounded semaglutide or tirzepatide, the FDA's April 2026 proposal could change your access. Here's the practical impact on your prescription.

Impact on Current Prescriptions

If your prescription is filled through a 503B outsourcing facility, this proposal directly affects your provider's ability to continue compounding GLP-1 medications. If your prescription goes through a 503A traditional pharmacy, the direct impact is less immediate — 503A pharmacies operate under separate authority.

Either way, your current prescription continues during the comment and rulemaking period. No immediate disruption.

What to Ask Your Provider

1. "Does my medication come from a 503A or 503B pharmacy?"
2. "How will the FDA's proposal affect my prescription continuity?"
3. "What's your contingency plan if the final rule passes?"
4. "Can you switch me to a 503A pharmacy if needed?"

Alternative Pathways

If compounded access becomes restricted, these options exist:

• Oral Wegovy: $149/month, brand-name, FDA-approved
• Manufacturer savings programs: Both Novo Nordisk and Eli Lilly offer significant discounts
• 503A pharmacy compounding: Patient-specific prescriptions through traditional pharmacies
• Insurance appeals: Coverage denials can often be overturned with documentation of medical necessity

The Bottom Line

Don't stop treatment. The rulemaking process takes months to years. Your current prescription continues. Use this window to understand your provider's pharmacy type and have a backup plan ready. Brand-name pricing, especially oral Wegovy at $149, has made the transition less financially painful than it would have been even a year ago.